Massar Capital Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Massar Capital Management’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-400,000	Closed	-$1.42M	–	400
2025 Q4	$1.42M	Hold	400,000	–	–	0.15%	109
2025 Q3	$1.4M	Hold	400,000	–	–	0.18%	77
2025 Q2	$820K	Buy	400,000 +300,000	+300%	+$750K	0.61%	50
2025 Q1	$114K	Buy	+100,000	New	+$77.4K	0.13%	93

Other funds holding STLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Massar Capital Management's STLN Position: Q1 2026 in Review

Massar Capital Management sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2026, closing a stake of 400,000 shares — an estimated $1.42M sold.

Massar Capital Management first reported a position in STLN in Q1 2025 and held it in 4 quarters. The position peaked at $1.42M in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

Massar Capital Management reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
Massar Capital Management sold 400,000 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $1.42M.
Massar Capital Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2025 and held it in 4 quarters.
Massar Capital Management's Starling Oncology Institute, Inc. Common Stock position peaked at $1.42M in Q4 2025.
115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Massar Capital Management's 13F filing for Q1 2026, filed 15 May 2026.